|
|
 |
|
¡¡ |
|
¡¡ |
|
|
|
¡¡ |
HOME > ÇÐȸ°£Ç๰ >
¿ë¾î»çÀü |
|
Á¦¸ñ |
A STUDY OF ANTI-PGL-1 ANTIBODY (IgM and IgG) UNDER MULTIDRUG THERAPY IN LEPROSY PATIENTS |
|
|
|
|
ÀúÀÚ |
Koo Weon Jeong |
¼Ò¼Ó |
Institute for Leprosy Research, KLCA |
|
|
³âµµ |
1990 |
±Ç |
23 |
|
|
È£ |
1 |
¹øÈ£ |
|
|
|
½ÃÀÛÆäÀÌÁö |
29 |
³¡ÆäÀÌÁö |
40 |
|
|
÷ºÎ |
|
|
|
¿ä¾à |
Anti-PGL-1 IgM and IgG antibody titers were examined by ELISA using ND-O-BSA against sera from 669 patients with leprosy, 214 contacts and 295 normal persons as control group. The results obtained were summerized as follows: 1. The mean absorbance and positive rate of anti-PGL-1 IgM antibody was 0.826(80%) in multibacillary, 0.309(46%) in paucibacillary leprosy patients, 0.117(15%) in contacts and 0.056(8%) in normal control persons and the highest in multibacillary group. 2. The more the bacterial index increased the more antibody titers increased. 3. The average IgM antibody titer in multibacillary cases tended to decrease acoording to the duration of multidrug therapy, but IgG antibodies were very low in general. 4. Following up serially for 2 years after initiation of multidrug therapy in 16 new patients and 5 relapsed patients, all cases except 2 cases showed positive IgM antibody and high positive(over 1,000) was 67% (14/21) before treatment. There was a decreasing tendency of IgM antibody titers during the first 2 years after initiation of multidrug therapy. IgG antibodies, on the other hand, were generally low. |
|
|
³»¿ë |
|
 | |
¡¡ |
|
|
|
|
|
|
|
|